In this section:

Substances: Epoetin Delta (Dynepo)

Dynepo is the trademark name for an erythropoiesis stimulating protein, epoetin delta. This protein, which stimulates red blood cell production by the same mechanism as human erythropoietin (EPO), is manufactured by the US pharmaceutical company Transkaryotic Therapies (TKT).

An increase in red blood cells improves the amount of oxygen the blood can carry to the body's muscles. It may also increase the body's capacity to buffer lactic acid.

Dynepo has legitimate clinical use in the treatment of anaemia related to chronic renal (kidney) disease - specifically for patients receiving or about to undergo dialysis, to elevate and maintain red blood cell production.

Side effects

Because it is a relatively new drug, scientific and anecdotal evidence of its side effects are not readily available. However, the drug is very similar to EPO, and therefore it is expected to have similar side effects. This includes causing the blood to thicken excessively. The heart has to work harder to pump the thicker blood and the blood is more prone to clot.

Consequently, Dynepo use could increase the risk of heart attack, stroke and clots in the lung. The risk is exacerbated by dehydration, which often occurs during endurance exercise.

Status in Sport

Dynepo is prohibited both in and out of competition under the World Anti-Doping Code 2007 Prohibited List (effective from 01/01/07).

 

Login:

Athletes’ Zone: